NCT04645550CompletedPhase 4
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
Efficacy and Safety of Apixaban, Warfarin and Aspirin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy
Source: ClinicalTrials.gov · Last updated 21 Mar 2025
Brief summary (registry, in English)
The purpose of this study is to determine whether Apixaban, Warfarin and Aspirin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (actual)
- First submitted
- 22 Nov 2020
- Start date
- 22 Nov 2020
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Northern Jiangsu People's Hospital
- Diseases
- High blood pressure
- NCT number
- NCT04645550
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 120
- From 22 Nov 2020 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hepatocellular carcinoma or any other malignancy
- Hypercoagulable state other than the liver disease related
- Recent peptic ulcer disease
- History of Hemorrhagic stroke
- Uncontrolled Hypertension
- Human immunodeficiency virus (HIV) infection
Lab values
- DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs
- Base line INR \>2
Other
- Child-Pugh grade C
- Pregnancy
Who the study is looking for
- A clinical, radiological or histologic diagnosis of cirrhosis of any etiology
- Splenomegaly with secondary hypersplenism
- No evidence of PVT or spleno-mesenteric thrombosis by ultrasound evaluation and angio-CT
- Informed consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Medical College of Yangzhou University Coordinator of this site? Confirm its status | Yangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.